Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype
- PMID: 11517108
- PMCID: PMC1718926
- DOI: 10.1136/adc.85.3.236
Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype
Abstract
Aims: To delineate common and variable features and outcome of children with congenital disorder of glycosylation type Ia (CDG-Ia) caused by the frequent R141H/F119L PMM2 genotype.
Methods: Clinical data on 25 patients (mean age 7.6 years, range 0-19) were analysed.
Results: All patients had an early presentation with severe feeding problems and failure to thrive, hypotonia, hepatic dysfunction, inverted nipples, and abnormal subcutaneous fat pads. Eighteen patients were hospitalised in the neonatal period. Developmental delay was obvious before age 6 months. During the first seven months mean standard deviation score (SDS) for weight and length decreased 2.7 (SD = 2) and 2.4 (SD = 2), respectively. Mental retardation, ataxia, muscular atrophy, and febrile seizures were consistent features after infancy. Variable features included pericardial effusions, afebrile seizures, and stroke like episodes. Computed tomography/magnetic resonance imaging of the brain was normal in two patients examined before 4 months of age, but 18 children examined after 3 months of age had cerebellar atrophy, and 10 children also had supratentorial atrophy. Subsequent imaging showed progression of the cerebellar and supratentorial atrophy in eight and four of 10 children, respectively. Mean head circumference SDS declined from zero to -1.9 SD from age 3 months to 5 years. Motor ability ranged from none to walking with a rolator, and vocabulary ranged from none to comprehensible speech. The overall mortality ascribed to CDG-Ia was 18%.
Conclusion: Patients with the R141H/F119L genotype have an early uniform presentation including severe failure to thrive, but their functional outcome is variable. This genotype may well cause clinical manifestations in the severe end of the spectrum of CDG-Ia.
Similar articles
-
Prepubertal growth in congenital disorder of glycosylation type Ia (CDG-Ia).Arch Dis Child. 2002 Oct;87(4):324-7. doi: 10.1136/adc.87.4.324. Arch Dis Child. 2002. PMID: 12244009 Free PMC article.
-
Ophthalmic manifestations of congenital disorder of glycosylation type 1a.Ophthalmic Genet. 2003 Jun;24(2):81-8. doi: 10.1076/opge.24.2.81.13994. Ophthalmic Genet. 2003. PMID: 12789572
-
ALG6-CDG: a recognizable phenotype with epilepsy, proximal muscle weakness, ataxia and behavioral and limb anomalies.J Inherit Metab Dis. 2016 Sep;39(5):713-723. doi: 10.1007/s10545-016-9945-x. Epub 2016 Jun 10. J Inherit Metab Dis. 2016. PMID: 27287710
-
Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.J Med Genet. 2017 Dec;54(12):843-851. doi: 10.1136/jmedgenet-2017-104903. Epub 2017 Sep 27. J Med Genet. 2017. PMID: 28954837 Review.
-
The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia).Biochim Biophys Acta. 2009 Sep;1792(9):827-34. doi: 10.1016/j.bbadis.2009.01.003. Epub 2009 Jan 14. Biochim Biophys Acta. 2009. PMID: 19272306 Review.
Cited by
-
Genotype-Phenotype Correlations in PMM2-CDG.Genes (Basel). 2021 Oct 21;12(11):1658. doi: 10.3390/genes12111658. Genes (Basel). 2021. PMID: 34828263 Free PMC article.
-
Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature.J Inherit Metab Dis. 2017 Mar;40(2):195-207. doi: 10.1007/s10545-016-0012-4. Epub 2017 Jan 20. J Inherit Metab Dis. 2017. PMID: 28108845 Review.
-
Targeted polymerase chain reaction-based enrichment and next generation sequencing for diagnostic testing of congenital disorders of glycosylation.Genet Med. 2011 Nov;13(11):921-32. doi: 10.1097/GIM.0b013e318226fbf2. Genet Med. 2011. PMID: 21811164 Free PMC article.
-
Revisiting the immunopathology of congenital disorders of glycosylation: an updated review.Front Immunol. 2024 Mar 14;15:1350101. doi: 10.3389/fimmu.2024.1350101. eCollection 2024. Front Immunol. 2024. PMID: 38550576 Free PMC article. Review.
-
Motor improvement in children with PMM2-CDG syndrome following a six-month rehabilitation treatment utilising whole-body vibration; a retrospective study.J Musculoskelet Neuronal Interact. 2024 Mar 1;24(1):12-21. J Musculoskelet Neuronal Interact. 2024. PMID: 38427364 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources